- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05517655
BEGIN Nouveaux biomarqueurs d'imagerie (BEGINNING)
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The overall hypothesis is that multi-organ MRI will provide more sensitive, robust outcome measures in young CF patients than traditional measures employed in the BEGIN study and that these novel measures will be more sensitive to treatment effects, tested here by comparison before and after triple-combination modulator therapy. By understanding the nature of early lung obstruction and characteristic changes in the liver and pancreas over time, we continue to lay the groundwork for more personalized medicine in the future.
Assessing treatment response and clinical benefit in children with CF who are clinically normal per standard outcomes (e.g., spirometry, pancreatic function) will become paramount as triplecombination therapy is extended to younger patients with milder CF clinical presentation than their historic peers. Here the sensitivity and profile free of ionizing-radiation exposure of MRI can be leveraged to follow an individual with CF over time to quantify changes with therapy-with additional spatial resolution unavailable from standard clinical testing.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45229
- Carrie Stevens
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- University of Virginia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Written informed consent (and assent where appropriate) obtained from the subject or subject's legal representative.
-
Willingness to adhere to the study-visit schedule and other protocol requirements.
-
Ages 6-8 years old at baseline MRI visit (may be enrolled up to 60 days before 6th birthday).
-
Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- Sweat chloride equal to or greater than 60 mEq/liter by quantitative pilocarpine iontophoresis test
- Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
-
Physician intent to prescribe triple-combination therapy
-
Clinically-stable with no respiratory tract infection at the time of enrollment.
-
No change in chronic maintenance therapies in the 28 days prior to enrollment.
-
Ability to cooperate with MRI procedures
Exclusion Criteria:
- Individuals currently on ivacaftor therapy (including Kalydeco, Orkambi, and Symdeko) and with at least one gating mutation. Gating mutations include G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, or G1349D.
- Acute respiratory symptoms (e.g. wheezing) at the time of the MRI.
- Acute respiratory infection, defined as increased cough, wheezing or respiratory rate in the 28 days prior to enrollment.
- Chronic lung disease not related to CF
- Chronic liver disease not related to CF
- Acute pancreatitis, defined by clinical criteria (45).
- Chronic pancreatic disease not related to CF.
- Physical findings that would compromise the safety of the subject or the quality of the study data as determined at the discretion of the site investigator.
- Any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pre Trikafta
129Xe MRI |
Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation. |
|
Expérimental: Post Trikafta
129Xe MRI |
Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Ventilation Defect Percentage change from baseline
Délai: 1 year
|
For pulmonary MRI, the primary outcome measure is the change in 129Xe ventilation defect percentage (VDP) from pre-therapy baseline to the one-year follow-up visit. |
1 year
|
|
Pancreas volume
Délai: 1 year
|
For pancreatic MRI, the primary outcome measure is change in pancreas volume normalized to BSA between pre-therapy baseline and one-year follow-up visit. |
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Abdominal T1 values
Délai: 1 year
|
Changes in MRI T1 average in the liver and pancreas, from baseline to follow up at 1 year |
1 year
|
|
Lung reader score
Délai: 1 year
|
Changes in reader score for visible structural defects from proton MRI, from baseline to follow up at 1 year |
1 year
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Jason Woods, PhD, Children's Hospital Medical Center, Cincinnati
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2021-0325
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .